SOURCE: Cutting Edge Information

October 14, 2008 08:18 ET

Cutting Edge Information's New Therapeutic Area Study Examines Diabetes Drugs, Classes, and Market Leaders

RESEARCH TRIANGLE PARK, NC--(Marketwire - October 14, 2008) - Pharmaceutical business intelligence firm Cutting Edge Information announces the release of its new study on the global diabetes market.

"Diabetes Market Forecast to 2013" examines the relevant trends affecting the diabetes space today and their impact leading into the next decade. It details the historical, current and forecasted performance of over 50 drugs treating diabetes and its complications -- marketed brands, pipeline products and those in clinical development -- and analyzes the top seven drug makers in the diabetes market.

A complimentary brochure is available for download at

To achieve breadth and depth, the report breaks diabetes data down by individual drug, class and company, and identifies which drug classes have the most potential in a highly competitive market. The report's structure leads to data comparisons and analysis across multiple levels. It enables an accurate and honest appraisal of key developments facing any or all players in the diabetes space, including identifying well-performing products and/or drug classes and emerging drug classes -- as well as major stumbling blocks such as patent expirations or negative clinical results.

"Diabetes patients have a wide range of treatment options and regimens," said Jeremy Spivey, the report's lead author. "In this increasingly aggressive market, our study will help companies differentiate themselves from the competition."

The products examined encompass antidiabetic non-insulin drugs, insulins and adjuncts. In terms of scope, CEI analysts considered antidiabetic drugs that are expected to generate more than $50 million at any point over the next five years.

The report is organized into brand profiles and drug manufacturer profiles.

Brand Profiles detail a product's competitive and strategic positioning, market opportunities, and patent and litigation data. Profiles include the following information:

--  Drug's current and projected competitive strength
--  Current/projected sales position within its class
--  Sales projection charts for the next four to seven years
--  Assessment of competition
--  Materiality charts
--  Clinical trial information

Company Profiles show breakdowns for seven companies that have established diabetes franchises or exciting development pipelines. Profiles contain:

--  Diabetes ranking
--  Overall industry ranking
--  Strengths analysis
--  Growth areas analysis
--  Competition analysis
--  Key products breakdown

Contact Information